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The topic I have chosen to research is heart 
failure.  I have chosen this topic because I 
have treated many patients in the ICU with 
this condition, and find it an interesting 
pathology.  Heart failure affects a significant 
portion of the patient population, and the 
rates are increasing.  5.1 million Americans 
≥20 years of age have heart failure, 
projections show that by 2030, the 
prevalence of HF will increase 25% from 
2013 estimates.  At 40 years of age, the 
lifetime risk of developing HF for both men 
and women is 1 in 5.  At 80 years of age, 
remaining lifetime risk for development of 
new HF remains at 20% for men and women, 
even in the face of a much shorter life 
expectancy.  While patients are now living 
longer after initial diagnosis, about half of 
the patients diagnosed die within five years.  
Projections from the American Heart 
Association show in 15 years, the total cost 
of HF will increase almost 120% to $70 billion 
from the current estimated total cost of $32 
billion.   
Signs and Symptoms 
The symptoms of heart failure can be divided 
into two categories; typical and less typical.  
Typical symptoms include shortness of 
breath, orthopnea, paroxysmal nocturnal 
dyspnea, decreased activity tolerance, 
fatigue/tiredness, and ankle swelling.  Less 
typical symptoms include wheezing, 
nocturnal cough, weight gain(more than 2 kg 
in a week), weight loss(in advanced heart 
failure), loss of appetite, confusion more 
common in elderly), depression, palpitations, 
and syncope. 
Signs of heart failure can also be divided into 
two categories; specific and less specific.  
Specific signs include elevated jugular 
pressure, hepato-jugular reflux, a third heart 
sound(gallop), laterally displaced apical 
impulse, and cardiac murmur.  Less specific 
signs include sacral or scrotal edema, 
tachycardia, irregular pulse, tachypnea, 
hepatomegaly, ascites, and cachexia.  
the echocardiogram and electrocardiogram 
(ECG) are the most useful tests in patients 
with suspected HF. A variety of ECG findings 
may occur for a patient in heart failure, and 
no sole specific abnormality is indicative of 
heart failure.  However, less than 2% of 
patients with heart failure will have a normal 
ECG.  This means that heart failure should at 
least be considered as a diagnosis in patients 
with any ECG abnormalities.   
The specific ECG abnormality may be used 
to guide treatment of HF.  The 
echocardiogram provides immediate 
information on chamber volumes, 
ventricular systolic and diastolic function, 
wall thickness, and valve function.  The 
echocardiogram is central not only in the 
diagnosis of heart failure, but also in the 
identification of which specific type of 
heart failure.  Findings and their 
corresponding abnormalities and 
implications can be seen in the table below 
Underlying Pathology 
Heart failure is a disease that results from 
the body compensating for a drop in 
cardiac output or blood pressure.  
Compensatory mechanisms help maintain 
cardiac output(increased contractility) and 
BP(vasoconstriction).  However, these 
compensatory changes over months and 
years can eventually worsen cardiac 
function. Any phenomenon that can cause 
impaired cardiac output or low blood 
pressure can therefore be a cause of 
heart failure, some examples include 
cardiac structural abnormalities, MIs, 
HTN, diabetes, and respiratory diseases.   
 
Sympathetic Nervous System – The 
Neurohumoral Response 
The hypothalamus begins the response to 
suboptimal cardiac output or BP. It begins 
the process by signaling for the adrenal 
glands to release epinephrine (EPI), and 
for noradrenergic neurons to release 
norepinephrine(NE).  EPI and NE target   
 
Beta affects 
Activation of beta1- and beta2-ARs is the 
most powerful physiologic mechanism to 
acutely increase cardiac performance. 
Beta 1-ARs activate Gs proteins whereas 
beta 2-ARs use both Gs and Gi proteins. 
Gs signaling acts as a “receptor-
accelerator,” and Gi signaling as a 
“receptor-brake”. Gs signaling stimulates 
the effector enzyme, adenyl cyclase, 
resulting in dissociation of adenosine 
triphosphate (ATP) into the second 
messenger(cAMP), which in turn binds to 
cAMP-dependent protein kinase A. 
Targets of protein kinase A-induced 
phosphorylations in the AR signaling 
pathway are: 
1) the L-type calcium channels and 
ryanodine receptors, causing an increase 
in calcium entry into the cell.  
 
Renin-Angiotensin-Aldosterone System 
The RAAS plays an important role in 
increasing vascular volume and vascular 
resistance.  RAAS is activated by beta 1, low 
BP, or low sodium in the kidneys.  When 
renin is released into the blood, it acts 
upon a circulating substrate, 
angiotensinogen, that undergoes 
proteolytic cleavage to form angiotensin I. 
Vascular endothelium, particularly in the 
lungs, has angiotensin converting enzyme 
(ACE), that cleaves off two amino acids to 
form the octapeptide, angiotensin II (AII), 
although many other tissues in the body 
(heart, brain, vascular) also can form AII.  
Angiotensin II has the following affects: 
-Arterial constriction, thereby increasing 
systemic vascular resistance and arterial 
pressure 
-Stimulates sodium transport 
(reabsorption) in renal tubules, increasing 
sodium and water retention 
- 
-Acts on the adrenal cortex to release 
aldosterone, which in turn acts on the 
kidneys to increase sodium and fluid 
retention 
-Stimulates the release of vasopressin 
(antidiuretic hormone, ADH) from the 
posterior pituitary, which increases fluid 
retention by the kidneys 
-Stimulates thirst 
-Facilitates norepinephrine release from 
sympathetic nerve endings and inhibits 
norepinephrine re-uptake by nerve 
endings, thereby enhancing sympathetic 
adrenergic function 
 
Remodeling 
Once the above phenomenon have taken 
place, the remodeling process results, which 
is what puts a patient into heart failure.  
Although an exact picture of all the 
pathways and cells involved in remodeling is 
still unclear, the following scenario has been 
proposed at a molecular level. As myocytes 
stretch, local norepinephrine activity and 
angiotensin and endothelin release are 
increased.  These changes stimulate 
expression of altered proteins and myocyte 
hypertrophy. The end result is further 
deterioration in cardiac performance and 
increased neurohormonal activation. In 
addition, increased activation of 
aldosterone and cytokines may also 
stimulate collagen synthesis, thus leading to 
fibrosis and remodeling of the extracellular 
matrix.  The heart becomes enlarged to the 
point that it does not pump blood 
effectively, and signs and symptoms of 
heart failure begin. 
 
Right Sided vs. Left Sided Failure 
While much of the molecular process is the 
same for right heart failure as it is for left 
heart failure, the affects are different.  
Instead of fluid backing up into the lungs as 
it does with left sided failure, fluid backs up 
into the venous system, causing swelling in 
the periphery, typically in the lower 
extremities.   
 
.   
Rates of heart failure are increasing. 
Understanding the pathology and 
progression of the disease can help 
healthcare providers assist patients in their 
management of heart failure.  Patient 
education and adherence to treatment plans 
is very important in successfully managing 
the disease, and improving quality of life.   
 
Conclusions 
Individuals diagnosed with heart failure 
may be treated medically and with lifestyle 
modifications.  To avoid fluid overload, salt 
intake should be restricted to 2-3g sodium 
diets.  Fluid restriction is also 
recommended, and patients should weigh 
themselves frequently to monitor their 
status.  Exercise should be encouraged.  
Medical management includes the use of 
diuretics to decrease fluid overload, 
nitrates to reduce vascular resistance, and 
beta blockers to suppress sympathetic 
stimulation of heart rate, contractility, and 
vasoconstriction.  ACE inhibitors may be 
prescribed to interrupt the renin-
angiotensin-aldosterone system’s affects.  
Treatments of chronic heart failure do not 
cure the disease, but slow its progression 
and make symptoms more manageable.   
Patients in acute heart failure will need 
emergent intervention, including 
administration of nitrates and diuretics as 
appropriate with BP.  Inotropic agents are 
generally not recommended unless the 
patient is in cardiogenic shock, because 
inotropic drugs increase the workload of 
the heart.  If cardiac output is severely 
compromised, inotropic meds may be 
considered.  Dobutamine is the inotrope of 
choice for increasing cardiac output, blood 
pressure, and peripheral circulation.  In the 
patient with heart failure that has produced 
pulmonary edema, CPAP may be 
considered 
 
Nursing Implications 
The heart wall does not have enough muscle 
mass to overcome the increased amount of 
blood in the ventricle, so a less than optimal 
amount of blood is ejected.  In diastolic heart 
failure(DHF), the remodeling process has 
resulted in an increased wall thickness, but 
the size of the left ventricular cavity has not 
increased, or has decreased.  The ventricular 
contraction ejects enough blood to result in a 
normal LVEF, but since the volume of blood 
in the ventricle before the contraction was 
lower than normal, ejecting a normal 
percentage of it is still inadequate.  
   
  
 
 
adrenergic receptors, with the beta 1, beta 
2, and alpha 1 receptors having the greatest 
affect on cardiac performance. 
   
Alpha affects 
Alpha1-ARs heavily populate major arteries 
(including the aorta,  
pulmonary arteries, mesenteric vessels, 
and coronary arteries) and activation of 
these receptors is a major contributor to 
the regulation of blood flow because 
they trigger vasoconstriction, resulting in 
increased cardiac output.    
  
 
2) the hyperpolarization-activated cyclic 
nucleotide-gated channels, which 
generate the hyperpolarization-
activated cation inward current, 
stimulating pacemaker cells of the heart 
to increase the heart rate. 
 3) phospholamban, a modulator of the 
sarcoplasmic reticulum associated ATP-
dependent calcium pump, which 
increases calcium reuptake by the 
sarcoplasmic reticulum, accelerating 
cardiac relaxation. 
4) troponin I and myosin binding 
protein-C, which reduce myofilament 
sensitivity to calcium, accelerating the 
relaxation of myofilaments. 
 5) phospholemman, a subunit of 
Na+/K+-ATPase, relieving its inhibitory 
influence and resulting in the 
stimulation of the sodium pump. 
These affects combine to increase heart 
rate and contractility.   
 
Systolic vs. Diastolic Failure 
Once the diagnosis of heart failure has been 
made, the diagnosis may be classified as 
systolic or diastolic failure.   This 
differentiation is primarily made using the 
left ventricular ejection fraction(LVEF), 
revealed by an echocardiogram.  A reduced 
LVEF is indicative of systolic heart failure, 
while a normal result indicates the failure is 
diastolic.  The neurohormonal process is 
similar for both types of failure, the 
difference originates from the remodeling 
process. 
In systolic heart failure(SHF), the 
remodeling process has resulted in a larger 
left ventricle and larger left ventricular 
cavity, but the wall thickness is decreased 
or unchanged. 
Diastolic heart failure involves thickened heart muscle that reduces maximum 
filling volume of ventricles.  Systolic heart failure features thin heart muscle 
that is too weak to eject the increased volume of blood filling the larger 
ventricles. 
